Influenza A virus and its antiviral drug treatment options

2022 Bouvier, 2008, The biology of influenza viruses, Vaccine, 26, D49, 10.1016/j.vaccine.2008.07.039 Air, 2012, Influenza neuraminidase, Influenza and other respiratory viruses, 6, 245, 10.1111/j.1750-2659.2011.00304.x 2016 Noda, 2012, Native morphology of influenza virions, Front Microbiol, 2, 269, 10.3389/fmicb.2011.00269 Montalto, 2000, Updated treatment for influenza A and B, Am Fam Physician, 62, 2467 2022 Gaitonde, 2019, Influenza: diagnosis and treatment, Am Fam Physician, 100, 751 Chen, 2018, Host immune response to influenza A virus infection, Front Immunol, 9, 320, 10.3389/fimmu.2018.00320 Schultz-Cherry, 2010, Influenza vaccines: the good, the bad, and the eggs, Adv Virus Res, 77, 63, 10.1016/B978-0-12-385034-8.00003-X 2022 Leider, 2010, Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?, Transfusion, 50, 1384, 10.1111/j.1537-2995.2010.02590.x Xu, 2020, Efficacy of convalescent plasma for the treatment of severe influenza, Crit Care, 24, 1, 10.1186/s13054-020-03189-7 Mair, 2014, Receptor binding and pH stability—how influenza A virus hemagglutinin affects host-specific virus infection, Biochim Biophys Acta Biomembr, 1838, 1153, 10.1016/j.bbamem.2013.10.004 Suzuki, 2005, Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses, Biol Pharm Bull, 28, 399, 10.1248/bpb.28.399 Thompson, 2006, Infection of human airway epithelium by human and avian strains of influenza a virus, J Virol, 80, 8060, 10.1128/JVI.00384-06 Wan, 2006, Quail carry sialic acid receptors compatible with binding of avian and human influenza viruses, Virology, 346, 278, 10.1016/j.virol.2005.10.035 Steinhauer, 1999, Role of hemagglutinin cleavage for the pathogenicity of influenza virus, Virology, 258, 1, 10.1006/viro.1999.9716 Jalily, 2020, Put a cork in it: plugging the M2 viral ion channel to sink influenza, Antivir Res, 178, 10.1016/j.antiviral.2020.104780 O'Neill, 1995, Nuclear import of influenza virus RNA can Be mediated by viral nucleoprotein and transport factors required for protein import (∗), J Biol Chem, 270, 22701, 10.1074/jbc.270.39.22701 2012, 93 Bourmakina, 2003, Reverse genetics studies on the filamentous morphology of influenza A virus, J Gen Virol, 84, 517, 10.1099/vir.0.18803-0 Barman, 2001, Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses, Virus Res, 77, 61, 10.1016/S0168-1702(01)00266-0 Donald, 1954, Counts of influenza virus particles, Microbiology, 10, 457 Enami, 1991, An influenza virus containing nine different RNA segments, Virology, 185, 291, 10.1016/0042-6822(91)90776-8 Barman, 2004, Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding, J Virol, 78, 5258, 10.1128/JVI.78.10.5258-5269.2004 Jung, 2020, Host protective immune responses against influenza A virus infection, Viruses, 12, 504, 10.3390/v12050504 Hayden, 2019, Influenza virus polymerase inhibitors in clinical development, Curr Opin Infect Dis, 32, 176, 10.1097/QCO.0000000000000532 Mullard, 2018, FDA approves first new flu drug in 20 years, Nat Rev Drug Discov, 17, 853 Hubsher, 2012, Amantadine: the journey from fighting flu to treating Parkinson disease, Neurology, 78, 1096, 10.1212/WNL.0b013e31824e8f0d Kumar, 2018, The emerging influenza virus threat: status and new prospects for its therapy and control, Arch Virol, 163, 831, 10.1007/s00705-018-3708-y Cáceres, 2021, Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 within vivoantiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses, Emerg Microb Infect, 10, 1832, 10.1080/22221751.2021.1972769 Hu, 2017, An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses, Antivir Res, 140, 45, 10.1016/j.antiviral.2017.01.006 Musharrafieh, 2020, Investigation of the drug resistance mechanism of M2-S31N channel blockers through biomolecular simulations and viral passage experiments, ACS Pharmacol Translat Sci, 3, 666, 10.1021/acsptsci.0c00018 Musharrafieh, 2020, Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26i and M2-S31N/V27A from the influenza A viruses, Eur J Pharmaceut Sci, 141, 10.1016/j.ejps.2019.105124 Hay, 1985, The molecular basis of the specific anti-influenza action of amantadine, EMBO J, 4, 3021, 10.1002/j.1460-2075.1985.tb04038.x Suzuki, 2003, Emergence of amantadine-resistant influenza A viruses: epidemiological study, J Infect Chemother, 9, 195, 10.1007/s10156-003-0262-6 Wintermeyer, 1995, Rimantadine: a clinical perspective, Ann Pharmacother, 29, 299, 10.1177/106002809502900312 Miller, 1994, New Rx for influenza A: flumadine, Geriatr Nurs, 15, 113, 10.1016/S0197-4572(09)90032-5 Bresee, 2011 O'Hanlon, 2019, Baloxavir marboxil: the new influenza drug on the market, Curr Opinion Virol, 35, 14, 10.1016/j.coviro.2019.01.006 Noda, 2012, Native morphology of influenza virions, Front Microbiol, 2, 269, 10.3389/fmicb.2011.00269 Herz, 1981, Influenza virus, an RNA virus, synthesizes its messenger RNA in the nucleus of infected cells, Cell, 26, 391, 10.1016/0092-8674(81)90208-7 DuBois, 2012, Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease, PLoS Pathog, 8, 10.1371/journal.ppat.1002830 Zhang, 2019, Focusing on the influenza virus polymerase complex: recent progress in drug discovery and assay development, Curr Med Chem, 26, 2243, 10.2174/0929867325666180706112940 Takashita, 2020, Influenza polymerase inhibitors: mechanisms of action and resistance, Cold Spring Harbor Perspect Med, 11, 10.1101/cshperspect.a038687 Davies, 2010, Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations, J Antimicrob Chemother, 65 Wagner, 2002, Functional balance between haemagglutinin and neuraminidase in influenza virus infections, Rev Med Virol, 12, 159, 10.1002/rmv.352 Feng, 2012, Recent advances in neuraminidase inhibitor development as anti-influenza drugs, ChemMedChem, 7, 1527, 10.1002/cmdc.201200155 Moscona, 2005, Neuraminidase inhibitors for influenza, N Engl J Med, 13, 1363, 10.1056/NEJMra050740 He, 1999, Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802, Clin Pharmacokinet, 37, 471, 10.2165/00003088-199937060-00003 FDA approves a second drug for the prevention of influenza A and B in adults and children. (n.d.). Retrieved January 1, 2023, from https://web.archive.org/web/20100306174033/https:/www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108622.htm. Zanamivir (n.d.). Retrieved January 1, 2023, from https://www.sciencedirect.com/topics/neuroscience/zanamivir. Martin, 2011, Peramivir: a new drug for influenza, Infect Dis Clin Pract, 19, 11, 10.1097/IPC.0b013e3181f5e967 205834ORIG1S000 - accessdata.fda.gov. (n.d.). Retrieved January 1, 2023, from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000Approv.pdf. Li, 2015, Inhibitors targeting the influenza virus hemagglutinin, Curr Med Chem, 22, 1361, 10.2174/0929867322666150227153919 Zhang, 2019, Targeting hemagglutinin: approaches for broad protection against the influenza A virus, Viruses, 11, 405, 10.3390/v11050405 Yang, 2013, Influenza A virus entry inhibitors targeting the hemagglutinin, Viruses, 5, 352, 10.3390/v5010352 Kadam, 2016, Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol, Proc Natl Acad Sci USA, 114, 206, 10.1073/pnas.1617020114 Stiver, 2003, The treatment of influenza with antiviral drugs, CMAJ (Can Med Assoc J), 168, 49 Aoki, 1988, Clinical pharmacokinetics of amantadine hydrochloride, Clin Pharmacokinet, 14, 35, 10.2165/00003088-198814010-00003 Shirley, 2020, Baloxavir marboxil: a review in acute uncomplicated influenza, Drugs, 80, 1109, 10.1007/s40265-020-01350-8 Baker, 2019, Baloxavir marboxil, Hosp Pharm, 54, 165, 10.1177/0018578719841044 Boltz, 2010, Drugs in development for influenza, Drugs, 70, 1349, 10.2165/11537960-000000000-00000 Naesens, 2016, Antiviral therapies on the horizon for influenza, Curr Opin Pharmacol, 30, 106, 10.1016/j.coph.2016.08.003 Ng, 2019, Xofluza (Baloxavir Marboxil) for the treatment of acute uncomplicated influenza, Pharm Therapeutic, 44, 9 Biddison, 1980, Human cytotoxic T cell responses to trinitrophenyl hapten and influenza virus. Diversity of restriction antigens and specificity of HLA-linked genetic regulation, J Exp Med, 152, 204s Kalamasz, 2004, Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies, J Immunother, 27, 405 Launay, 2008, Effect of sublingual administration of interferon-α on the immune response to influenza vaccination in institutionalized elderly individuals, Vaccine, 26, 4073, 10.1016/j.vaccine.2008.05.035 Boylston, 2012, The origins of inoculation, J R Soc Med, 105, 309, 10.1258/jrsm.2012.12k044 World's first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above. (n.d.). Retrieved January 1, 2023, from https://pib.gov.in/PressReleasePage.aspx?PRID=1880328#:7E:text=World's%20first%20intra%2Dnasal%20vaccine,group%20of%2018%20and%20above. 2022 2021 Influenza (flu) vaccine (live, intranasal): what you need to know. (n.d.). Retrieved January 1, 2023, from https://www.cdc.gov/vaccines/hcp/vis/vis-statements/flulive.pdf. Lu, 2020, Gut microecology: why our microbes could be key to our health, Biomed Pharmacother, 131, 10.1016/j.biopha.2020.110784 Steed, 2017, The microbial metabolite desaminotyrosine protects from influenza through type I interferon, Science, 357, 498, 10.1126/science.aam5336 Winter, 1991, Clostridium orbiscindens sp. nov., a human intestinal bacterium capable of cleaving the flavonoid C-ring, Int J Syst Bacteriol, 41, 355, 10.1099/00207713-41-3-355 Gerber, 2000, Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection, Clin Infect Dis, 30, 10.1086/313857 Singh, 2009, Nanoparticle-based targeted drug delivery, Exp Mol Pathol, 86, 215, 10.1016/j.yexmp.2008.12.004 Dawre, 2021, 278 Chakravarty, 2020, Nanotechnology-based antiviral therapeutics, Drug Deliv Translat Res, 11, 748, 10.1007/s13346-020-00818-0 Mayer, 2005, Nanocapsules as drug delivery systems, Int J Artif Organs, 28, 1163, 10.1177/039139880502801114 Ochekpe, 2009, Nanotechnology and drug delivery part 2: nanostructures for drug delivery, Trop J Pharmaceut Res, 8 Singh, 2017, The role of nanotechnology in the treatment of viral infections, Therapeutic Advan Infectious Disease, 4, 105, 10.1177/2049936117713593 Murthy, 2007, Nanoparticles in modern medicine: state of the art and future challenges, International journal of nanomedicine, U.S. Nation Library Med Mischler Cojocaru, 2020, Nanomaterials designed for antiviral drug delivery transport across biological barriers, Pharmaceutics, 12, 171, 10.3390/pharmaceutics12020171 Shinde, 2022, Comparison of the safety and immunogenicity of a novel matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial, Lancet Infect Dis, 22, 73, 10.1016/S1473-3099(21)00192-4 Results from Novavax NanoFlu Influenza vaccine phase 3 clinical trial published in The lancet infectious diseases (2021) Novavax Investor Relations. Available at: https://ir.novavax.com/2021-09-23-Results-from-Novavax-NanoFlu-Influenza-Vaccine-Phase-3-Clinical-Trial-Published-in-The-Lancet-Infectious-Diseases.